SMS Pharmaceuticals Limited (SMSPHARMA.NS)
INR 241.75
(1.64%)
INR 241.75
(1.64%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.44 Billion INR | -0.86% |
| 2022 | 2.46 Billion INR | 13.85% |
| 2021 | 2.16 Billion INR | 1.18% |
| 2020 | 2.14 Billion INR | 45.16% |
| 2019 | 1.47 Billion INR | 14.39% |
| 2018 | 1.28 Billion INR | -3.39% |
| 2017 | 1.33 Billion INR | -15.79% |
| 2016 | 1.58 Billion INR | -7.23% |
| 2015 | 1.7 Billion INR | 17.23% |
| 2014 | 1.45 Billion INR | 5.78% |
| 2013 | 1.37 Billion INR | 45.5% |
| 2012 | 947.13 Million INR | -44.45% |
| 2011 | 1.7 Billion INR | -5.87% |
| 2010 | 1.81 Billion INR | 14.6% |
| 2009 | 1.58 Billion INR | 35.25% |
| 2008 | 1.16 Billion INR | 70.97% |
| 2007 | 683.58 Million INR | 307.98% |
| 2006 | -328.67 Million INR | -154.4% |
| 2005 | 604.22 Million INR | 3.18% |
| 2004 | 585.6 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 362.02 Million INR | -85.2% |
| 2023 Q4 | 2.44 Billion INR | 642.81% |
| 2023 FY | 2.44 Billion INR | -0.86% |
| 2023 Q1 | 74.69 Million INR | -96.97% |
| 2023 Q2 | 2.43 Billion INR | 3164.6% |
| 2023 Q3 | 329.24 Million INR | -86.5% |
| 2022 Q2 | 2.53 Billion INR | 442.79% |
| 2022 FY | 2.46 Billion INR | 13.85% |
| 2022 Q3 | 5.5 Million INR | -99.78% |
| 2022 Q4 | 2.46 Billion INR | 44744.41% |
| 2022 Q1 | 466.6 Million INR | -78.47% |
| 2021 Q4 | 2.16 Billion INR | 620.15% |
| 2021 Q1 | 405.09 Million INR | -81.08% |
| 2021 FY | 2.16 Billion INR | 1.18% |
| 2021 Q2 | 2.16 Billion INR | 435.5% |
| 2021 Q3 | 300.89 Million INR | -86.13% |
| 2020 Q3 | 65.94 Million INR | -95.25% |
| 2020 Q1 | 96.53 Million INR | -93.46% |
| 2020 FY | 2.14 Billion INR | 45.16% |
| 2020 Q4 | 2.14 Billion INR | 3147.29% |
| 2020 Q2 | 1.38 Billion INR | 1337.3% |
| 2019 Q4 | 1.47 Billion INR | 1555.63% |
| 2019 Q3 | 89.1 Million INR | -91.88% |
| 2019 Q2 | 1.09 Billion INR | 0.0% |
| 2019 FY | 1.47 Billion INR | 14.39% |
| 2018 FY | 1.28 Billion INR | -3.39% |
| 2018 Q4 | 1.28 Billion INR | 0.0% |
| 2017 FY | 1.33 Billion INR | -15.79% |
| 2016 Q2 | 1.49 Billion INR | 0.0% |
| 2016 FY | 1.58 Billion INR | -7.23% |
| 2015 FY | 1.7 Billion INR | 17.23% |
| 2015 Q4 | 1.7 Billion INR | 2285.7% |
| 2015 Q3 | 71.63 Million INR | -95.75% |
| 2015 Q2 | 1.68 Billion INR | 2549.08% |
| 2015 Q1 | 63.63 Million INR | -95.63% |
| 2014 Q2 | 1.39 Billion INR | 1061.24% |
| 2014 Q1 | 120.5 Million INR | -91.26% |
| 2014 FY | 1.45 Billion INR | 5.78% |
| 2014 Q4 | 1.45 Billion INR | 2465.3% |
| 2014 Q3 | 56.82 Million INR | -95.94% |
| 2013 Q1 | 614.63 Million INR | -35.11% |
| 2013 Q4 | 1.37 Billion INR | 3533.88% |
| 2013 Q3 | 37.92 Million INR | -96.83% |
| 2013 Q2 | 1.19 Billion INR | 94.37% |
| 2013 FY | 1.37 Billion INR | 45.5% |
| 2012 Q4 | 947.13 Million INR | 0.0% |
| 2012 FY | 947.13 Million INR | -44.45% |
| 2011 FY | 1.7 Billion INR | -5.87% |
| 2011 Q4 | 1.7 Billion INR | 0.0% |
| 2010 FY | 1.81 Billion INR | 14.6% |
| 2009 FY | 1.58 Billion INR | 35.25% |
| 2008 FY | 1.16 Billion INR | 70.97% |
| 2007 FY | 683.58 Million INR | 307.98% |
| 2006 FY | -328.67 Million INR | -154.4% |
| 2005 FY | 604.22 Million INR | 3.18% |
| 2004 FY | 585.6 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Abbott India Limited | -20.51 Billion INR | 111.923% |
| Cipla Limited | -3.15 Billion INR | 177.503% |
| Gland Pharma Limited | -14.67 Billion INR | 116.668% |
| GlaxoSmithKline Pharmaceuticals Limited | -674.11 Million INR | 462.801% |
| Kopran Limited | 850.3 Million INR | -187.625% |
| Marksans Pharma Limited | -4.29 Billion INR | 156.94% |
| NGL Fine-Chem Limited | 307.22 Million INR | -696.058% |
| Pfizer Limited | -19.52 Billion INR | 112.528% |
| Sanofi India Limited | -3.87 Billion INR | 163.114% |
| TTK Healthcare Limited | -7.52 Billion INR | 132.517% |